Combinating Fingolimod With Alteplase Bridging With Thrombectomy in Acute Ischemic Stroke

Launched by SECOND AFFILIATED HOSPITAL, SCHOOL OF MEDICINE, ZHEJIANG UNIVERSITY · Dec 16, 2020

Keywords

ClinConnect Summary

This clinical trial is studying whether adding a medication called fingolimod to standard treatments for acute ischemic stroke (AIS) can improve outcomes for patients. Acute ischemic stroke occurs when blood flow to the brain is blocked, and this study specifically looks at patients who are receiving alteplase (a clot-busting drug) and mechanical thrombectomy (a procedure to remove the clot). The goal is to see if taking fingolimod within 24 hours of stroke symptoms starting can help reduce brain inflammation and improve recovery.

To be eligible for this trial, participants need to be between 18 and 85 years old and have experienced a specific type of stroke that affects the front part of the brain. They must also meet certain imaging criteria that show the extent of the stroke. Importantly, participants should not have significant pre-existing neurological disabilities or any reasons that would prevent them from safely taking fingolimod. If someone joins this trial, they will be closely monitored to assess how well the combination of treatments works and to ensure their safety.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients presenting with anterior circulation acute ischaemic stroke who are eligible for alteplase and mechanical thrombectomy commenced within 24 hours of stroke onset or awakening with stroke (if within 24 hours from the midpoint of sleep).
• • Patient's age is 18-85 years.
• • Arterial occlusion on CTA of the ICA, M1 or M2.
• • Imaging inclusion criteria: infarct core volume ≤ 100 mL and penumbra ≥ 15 mL with at least 20% mismatch (as evaluated by CTP).
• • Patient, family member or legally responsible person depending on local ethics requirements has given informed consent.
• Exclusion Criteria:
• • Pre-existing neurologic disability (a score greater than 2 on the mRS).
• • Contraindication of fingolimod.